Benralizumab (anti-IL5RA)

Benralizumab (anti-IL5RA) (MEDI-563 (anti-IL5RA) ; BIW-8405 (anti-IL5RA) ) is an interleukin-5 receptor α (IL-5Rα) -directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study [1][2].

Product Specifications

CAS Number

[1044511-01-4]

Product Name Alternative

MEDI-563 (anti-IL5RA) ; BIW-8405 (anti-IL5RA)

UNSPSC

12352203

Target

Apoptosis; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/benralizumab-anti-il5ra.html

Purity

99.60

Solubility

10 mM in DMSO

Smiles

[Benralizumab(anti-IL5RA)]

Molecular Weight

(146.08 kDa)

References & Citations

[1]Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5 (3) :00009-2019. Published 2019 Sep 25.|[2]Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125 (6) :1344-1353.e2.